Recent developments include the execution and termination of a merger agreement with HDEducation Group Limited, the execution of a merger agreement with Bioserica International Limited, shareholder approval of an extension to complete a business combination, and a share exchange increasing the Sponsor's ownership stake.

• On December 31, 2024, the company entered into an agreement with HDEducation Group Limited for a potential business combination, which was terminated by mutual agreement on May 21, 2025 [S1].
• On January 24, 2025, the company entered into a merger agreement with Bioserica International Limited, a bio-based antimicrobial materials company, with an aggregate consideration of approximately $217.86 million payable in stock [S1].
• On October 27, 2025, shareholders approved an extension amendment allowing the company up to 24 months from the IPO to consummate a business combination, extending the deadline to November 12, 2026 [S1].
• Following the shareholder vote, approximately $2.9 million remained in the Trust Account after redemptions totaling $59.5 million [S1].
• On January 16, 2026, the Sponsor transferred 1,499,900 Class B ordinary shares to the company in exchange for Class A ordinary shares, resulting in the Sponsor holding approximately 76.4% of the outstanding Class A shares [S1].

The company has executed a merger agreement with Bioserica International Limited, a company engaged in bio-based antimicrobial materials, which aligns with its stated focus on ESG and material technology sectors. The extension of the deadline to complete a business combination provides additional time to finalize the transaction. The company maintains liquidity and has a clear plan for deploying funds from the Trust Account to complete the business combination.

The company has not generated operating revenues and continues to incur costs related to its public company status and business combination efforts. The termination of a prior agreement with HDEducation Group Limited indicates challenges in closing deals. The remaining funds in the Trust Account after redemptions are limited, and failure to complete a business combination by the extended deadline will result in liquidation. The significant ownership concentration by the Sponsor may pose governance risks.

As a SPAC, ASPAC III Acquisition Corp. does not have an operating business or competitive moat. Its value proposition lies in its ability to identify and complete a business combination with a target company in its focus sectors. The company’s competitive position depends on the quality of its management team, its ability to negotiate favorable terms, and the attractiveness of its target acquisition. The Sponsor’s significant ownership stake aligns interests but also concentrates control.

• Business Combination Risk: There is no assurance that the company will successfully complete a business combination within the extended deadline, which would result in liquidation.
• Liquidity Risk: The company’s remaining funds in the Trust Account are limited after redemptions, which may constrain its ability to complete a business combination or cover expenses.
• Operational Risk: The company has no operating revenues and incurs ongoing costs related to being a public company and pursuing a business combination.
• Governance Risk: The Sponsor holds a significant majority of the company’s outstanding Class A shares, concentrating control and potentially impacting minority shareholder interests.

• ASPAC III Acquisition Corp. is a blank check company incorporated in the British Virgin Islands for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses [S1].
• The company intends to pursue prospective targets in the Environmental, Sustainability and Governance (ESG) and material technology sectors [S1].
• The company completed its IPO on November 12, 2024, issuing 6,000,000 units at $10.00 per unit, generating gross proceeds of $60 million, with $60 million placed in a Trust Account [S1].
• The Sponsor purchased 280,000 Private Placement Units for $2.8 million simultaneously with the IPO [S1].
• The company has incurred no operating revenues to date and has only engaged in organizational activities and searching for a business combination target [S1].
• The company entered into and later terminated an agreement with HDEducation Group Limited for a potential business combination [S1].
• The company entered into a merger agreement with Bioserica International Limited, a bio-based antimicrobial materials company, with an aggregate consideration of approximately $217.86 million payable in stock [S1].
• The merger agreement includes customary representations, warranties, covenants, and is subject to closing conditions [S1].
• The company completed an internal reorganization in September 2025 related to the merger structure [S1].
• In October 2025, shareholders approved an extension amendment allowing up to 24 months from the IPO to consummate a business combination, extending the deadline to November 12, 2026 [S1].
• Following the shareholder vote, approximately $2.9 million remained in the Trust Account after redemptions totaling $59.5 million [S1].
• The Sponsor holds approximately 76.4% of the company's outstanding Class A ordinary shares after a share exchange in January 2026 [S1].
• As of June 30, 2026, the company had cash and cash equivalents of $670,328 and current assets of $798,308, with current liabilities of $560,564, resulting in a current ratio of 1.42 and a cash ratio of 1.2 [S2].
• The company reported a net loss of $15,218 for the quarter ended June 30, 2026 [S2].
• The company reported basic and diluted earnings per share of -$0.03 for the quarter ended September 30, 2024 [S2].
• The company accounts for Class A ordinary shares subject to possible redemption as liabilities or temporary equity depending on redemption rights [S1].
• The company has no operating revenues and expects to generate income primarily from interest on marketable securities held in the Trust Account prior to a business combination [S1].
• The company has incurred significant costs related to being a public company and pursuing a business combination [S1].
• The company may seek additional financing to complete a business combination or to meet obligations post-combination [S1].
• If the company does not complete a business combination within 24 months from the IPO, it will proceed to voluntary liquidation [S1].
• The company has three independent directors as defined by NASDAQ listing standards [S1].
• The company’s investments held in the Trust Account are primarily in money market funds investing in U.S. government securities [S1].
• The company’s financial statements are audited by WWC, P.C., with audit fees disclosed [S1].
• The company’s recent news coverage includes an article on ownership structure published by www.nasdaq.com on August 19, 2021 [N1].